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Abstract
Background: HIV pre-exposure prophylaxis (PrEP), the use of antiretroviral drugs by uninfected individuals to prevent HIV
infection, has demonstrated effectiveness in preventing acquisition in a high-risk population of men who have sex with men
(MSM). Consequently, there is a need to understand if and how PrEP can be used cost-effectively to prevent HIV infection in
such populations.
Methods and Findings:We developed a mathematical model representing the HIV epidemic among MSM and transwomen
(male-to-female transgender individuals) in Lima, Peru, as a test case. PrEP effectiveness in the model is assumed to result
from the combination of a ‘‘conditional efficacy’’ parameter and an adherence parameter. Annual operating costs from a
health provider perspective were based on the US Centers for Disease Control and Prevention interim guidelines for PrEP
use. The model was used to investigate the population-level impact, cost, and cost-effectiveness of PrEP under a range of
implementation scenarios. The epidemiological impact of PrEP is largely driven by programme characteristics. For a modest
PrEP coverage of 5%, over 8% of infections could be averted in a programme prioritising those at higher risk and attaining
the adherence levels of the Pre-Exposure Prophylaxis Initiative study. Across all scenarios, the highest estimated cost per
disability-adjusted life year averted (uniform strategy for a coverage level of 20%, US$1,036–US$4,254) is below the World
Health Organization recommended threshold for cost-effective interventions, while only certain optimistic scenarios (low
coverage of 5% and some or high prioritisation) are likely to be cost-effective using the World Bank threshold. The impact of
PrEP is reduced if those on PrEP decrease condom use, but only extreme behaviour changes among non-adherers (over 80%
reduction in condom use) and a low PrEP conditional efficacy (40%) would adversely impact the epidemic. However, PrEP
will not arrest HIV transmission in isolation because of its incomplete effectiveness and dependence on adherence, and
because the high cost of programmes limits the coverage levels that could potentially be attained.
Conclusions: A strategic PrEP intervention could be a cost-effective addition to existing HIV prevention strategies for MSM
populations. However, despite being cost-effective, a substantial expenditure would be required to generate significant
reductions in incidence.
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Introduction
The use of antiretroviral (ARV) medicines for prevention of
acquisition or transmission of HIV is currently a focus of policy
discussions. The use of ARV drugs in HIV-uninfected individuals
to prevent HIV acquisition—pre-exposure prophylaxis (PrEP)—is
one of the alternatives being considered as a potential tool in the
HIV prevention arsenal [1]. In 2010, the results of the first phase
III clinical trial of PrEP were published: the Pre-Exposure
Prophylaxis Initiative (iPrEx) study was a multinational trial of
daily oral tenofovir/emtricitabine to prevent acquisition of HIV
among high-risk men who have sex with men (MSM) [2]. It
showed that this regime was safe and reduced the risk of HIV
acquisition by 44% [2]. Consequently, the World Health
Organization, the US Centers for Disease Control and Prevention,
the British Association for Sexual Health and HIV, and the South
African HIV Clinicians Society have published interim guidance
on PrEP [3–6] recommending its use as part of a programme of
comprehensive HIV prevention. Recently the US Food and Drug
Administration approved the use of ARV drugs (tenofovir/
emtricitabine, brand name Truvada) for use as PrEP among
men and women [7]. Consultations are taking place to inform
public health policy-makers in the development of clinical and
service guidelines regarding PrEP. Additionally, adding momen-
tum to this fast-moving field, PrEP was also found to be effective in
preventing acquisition of HIV among heterosexual men and
women in sub-Saharan Africa in some studies [8,9]. However,
FEM-PrEP, a trial recruiting heterosexual women in South Africa,
Tanzania, and Kenya was closed prematurely last year when the
data review committee stated that it would not be able to
demonstrate an effect of PrEP [10]. Two further trials have tested
the efficacy of 1% tenofovir gel, with somewhat inconsistent
results. The CAPRISA 004 trial found a reduction in women’s risk
by 39% [11], while the VOICE trial’s gel arm was stopped early
after finding the product safe but not effective [12]. There is,
therefore, a need to understand if and how PrEP could cost-
effectively prevent HIV infection in specific populations within the
current context of expanding access to treatment.
Although trials can demonstrate effectiveness in reducing an
individual’s chance of acquiring HIV, they do not show the extent
to which a PrEP intervention would reduce the spread of HIV at
the population level. Questions remain about how to optimally
implement PrEP when multiple forms of delivery, prioritisation,
and scale-up are possible in the context of other HIV prevention
interventions. In response, we have built and analysed a
mathematical model of the HIV epidemic among MSM and
transwomen (male-to-female transgender individuals) in Lima,
Peru. Mathematical models provide a framework to examine the
potential impact of interventions that may inform policy develop-
ment [13]. The HIV epidemic in Lima, Peru, is concentrated
among MSM, comparable to most of Latin America and multiple
high-income settings [14]. As such, it provides a ‘‘test case’’ for
which there are high-quality behavioural and epidemiological data
to adequately specify a mathematical model. Moreover, the
majority of iPrEx participants were recruited in Peru, allowing us
to include representative information on potential PrEP use. Our
analysis aims to provide information to assist the process of
translating recent trial results into cost-effective programmes.
Methods
In this paper, we present the potential benefits and costs of a
hypothetical PrEP intervention using a deterministic, compart-
mental model to represent the sexual transmission of HIV
amongst MSM and transwomen in Lima, Peru. Our aim was to
investigate the impact of a feasible intervention and to determine
the most efficient strategies for its roll out in this population. In
particular, we looked at the impact of coverage, adherence, and
prioritisation on both health benefits and costs to the health
system.
Lima has a diverse MSM population, which we defined as men
or transwomen who have reported a sexual partnership with a
man in the last 12 mo. To represent HIV spread in the model, we
defined four interacting groups: men who mostly have sex with
women (MMSW), men who mostly have sex with men (MMSM),
sex workers, and transwomen at higher risk (including transsex-
uals and transvestites who have a large number of partners on
average). These categories are intended to represent a broad
spectrum of sexual identities, orientations, and behaviours
encompassing variation in numbers of partners, types of
partnerships formed (stable, casual, commercial), condom use,
and sex work (defined as the exchange of anal sex for money,
drugs, gifts, or favours). Our subgroup definitions followed the
classification commonly used in research studies in Peru [14].
Some groups were further subdivided into mutually exclusive
compartments according to their sexual positioning in anal sex
(insertive, receptive, or versatile, i.e., practicing both insertive and
receptive anal sex), resulting in a total of nine groups (Figure 1;
more information on the group definitions can be found in Text
S1). To estimate the distribution of MSM into the different risk
groups, we reviewed studies describing the proportion of MSM
reporting sex with a woman in the last year and/or the
proportion of MSM self-identified as heterosexuals or bisexuals
(for MMSW), as homosexuals/gay (for MMSM), and as
transgender, transvestite, or transsexual. To estimate the propor-
tion of sex workers, we subtracted the proportions of MMSW,
MMSM, and transwomen from the total. We then compared this
estimate against reported proportions of MSM involved in sex
work during the last year [15–20]. Frequency of partnership
formation was based on reported number of sexual partners from
published studies and unpublished data from studies of trans-
women (transwomen study funded by amfAR) [21] and MSM
(CPOS study; C. Caceres and E. R. Segura, unpublished data).
Stable, casual, and commercial partnerships were defined by
frequencies of sex acts. For the versatile group, the total number
of sex acts was divided into a proportion of insertive or receptive
acts. Condom use was estimated from reported condom use data
at last sex act for different partnership types. If data were
available for both the insertive and receptive partners, the
probability of using a condom was determined by the receptive
partner. Receptive partners have a higher probability of infection
than insertive partners, and condom use thus has a higher impact
on the receptive partner. HIV prevalence in Lima among the
general population is low, and therefore the risk of transmission
to MSM and transgender people from other sources was not
included (tables detailing contact patterns by type of partnership,
HIV prevalence by group, group distributions, and demographic
and behavioural parameters used in the model can be found in
Text S1).
Following previous work, the natural course of HIV infection
was represented as four phases of disease progression defined by
duration and infectiousness: acute infection, latent phase, pre-
AIDS, and AIDS (see Text S1) [22–25]. A proportion of
individuals initiate antiretroviral treatment (ART) rather than
progress to pre-AIDS, depending on the coverage level. ART is
assumed to reduce infectiousness and extend survival [26].
Cost-Effectiveness of PrEP in MSM Populations
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Three sources of information were used to calibrate the model:
reported behaviour, HIV natural history, and data on prevalence
and incidence for MSM and transwomen subpopulations in Lima
(from the Peruvian Ministry of Health and published studies; these
sources and values are detailed in Text S1). We used a quasi-
Bayesian procedure to combine these sources of information and
account for uncertainty around parameter estimates [27,28]. This
procedure consists in allowing certain parameters to vary within a
specified prior distribution reflecting the uncertainty of the
estimates. The parameters allowed to vary describe the risk
distribution in the population and risk behaviours (presented in
Text S1). These are specific to each setting and are most
vulnerable to bias in the sampling method and to reporting bias.
The sampling of parameter values was carried out using Latin
hypercube sampling [29]. Each model run is the result of a
different combination of parameter values. Prior limits on
prevalence are defined in order to select plausible runs, and then
the best fitting set of parameters is determined using the log
likelihood (details on prior limits chosen are given in Text S1). Of
10,000 runs performed, 449 were selected and are shown in
Figure 2, together with the best fit based on prevalence data for the
four subgroups (MMSW, MMSM, sex workers, and transwomen
at higher risk) and the overall population. This best fit was then
used for the primary analyses. To ensure it was representative of
the most likely epidemiological scenario, we explored the
uncertainty due to the epidemiological assumptions and compared
the results obtained using the parameter set corresponding to the
best fit to those from all other runs selected in the Bayesian
process. The distribution of infections averted obtained from all
selected runs and the 50 best fits are presented in Text S1 and
compared to the estimates obtained from the best fit for the most
relevant scenarios.
Assumptions about the Pre-Exposure Prophylaxis
Intervention in the Model
PrEP effectiveness in the model is assumed to result from the
combination of a reduction in susceptibility to HIV infection
during a PrEP-protected sex act (‘‘conditional efficacy’’ parameter)
and a proportion of sex acts protected (adherence parameter). We
aimed to reflect a daily regimen of PrEP and an overall
effectiveness equivalent to that of the iPrEx trial, 44% (95% CI
15–63) [2]. In a retrospective analysis of data from the iPrEx trial,
for those with detectable levels of drug in their blood samples, HIV
incidence was reduced by 92% (95% CI 40–99). We interpreted
these findings to show an efficacy of PrEP that varies with
individual-level adherence, in accordance to results presented
recently in which biological determinants did not explain the
differential efficacy observed in the iPrEx trial [30]. We refer to
this parameter as a ‘‘conditional efficacy’’ in the model to reflect
an assumption of high intrinsic efficacy of PrEP (equivalent to
92%) but large population-level heterogeneity in adherence
behaviours. Therefore, we divided PrEP-users into three adher-
ence groups using point estimates: good (95%), average (45%), and
poor (15%). The proportion in each group was altered to reflect
three adherence profiles: the ‘‘iPrEx adherence’’ profile, for which
the proportions were as observed in the trial, and the ‘‘less
adherence’’ and ‘‘more adherence’’ scenarios. The adherence
profile in the ‘‘more adherence’’ scenario corresponds to the
hypothesis being tested in the open label extension of the iPrEx
trial looking at a possible increase in use of the study drug by
participants due to the participants’ knowledge of receiving an
active drug that provides some protection against HIV infection.
For all scenarios, when both the conditional efficacy and
adherence profiles are combined, the functional effectiveness
calculated reproduces the effectiveness observed in the iPrEx trial,
Figure 1. Model representation of sexual mixing and sexual positioning among MSM and transwomen. Insertive (Ins) and receptive
(Rec) men always take the insertive and receptive role during anal sex, respectively. Versatile (Ver) men take either the insertive or the receptive role
during anal sex. Arrows indicate sexual partnerships being formed between individuals within groups—the width shows the number of partnerships,
and the direction illustrates sexual positioning (from insertive towards receptive). For each category, insertive men will form partnerships only with
receptive men or versatile men (the latter in a receptive role); versatile men will form partnerships with insertive men, versatile men, or receptive men,
depending on their role per sex act; receptive men will form partnerships only with insertive men or versatile men (the latter in an insertive role).
doi:10.1371/journal.pmed.1001323.g001
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44% (95% CI 15–63) [2]. Table 1 shows the assumptions made for
conditional efficacy and adherence, as well as the resulting
functional effectiveness for each profile.
We constructed two scenarios for overall scale-up of PrEP
programmes: (i) ‘‘low coverage’’ and (ii) ‘‘high coverage’’,
whereby 5% and 20% of uninfected individuals use PrEP,
respectively. In both scenarios, scale-up begins in 2012, and
coverage is reached in 5 y and maintained thereafter for an
additional 5 y. We quantified the contribution of each subpop-
ulation to the number of future HIV infections and the relative
impact of PrEP if used in each group separately to identify key
points for an intervention. We looked at the impact of distributing
a fixed amount of PrEP (25,000 person-years, corresponding to a
10% resource allocation of the national prevention programme to
PrEP [31]) to each group in isolation. PrEP could then be
distributed evenly to all MSM and transwomen (‘‘uniform
coverage’’), or certain key groups could be prioritised for PrEP
allocation (‘‘prioritisation’’). Prioritised scenarios could result in
‘‘some prioritisation’’, where a higher coverage is achieved in key
populations such as the transwomen at higher risk and sex worker
groups (but no more than 50% coverage) than in MMSW and
MMSM, or in ‘‘high prioritisation’’: once 90% of the transwomen
at higher risk group receives PrEP, the residual amount (to
achieve 5% or 20% overall coverage) is divided among the three
other populations, prioritising sex workers over MMSW and
MMSM. Table 2 shows the coverage assumptions of PrEP for
each scenario.
Cost-Effectiveness Calculations
We estimated the annual operating costs of providing a
hypothetical PrEP intervention to individuals, from a health
provider perspective, based on the US Center for Disease Control
and Prevention interim guidelines for PrEP [3]. In accordance
with these clinical recommendations, we included costs for the
following procedures: HIV testing before starting PrEP, HIV
testing every 3 mo during use of PrEP, HIV confirmatory testing if
an individual is found positive, one creatinine/blood urea nitrogen
test per year during PrEP use, outreach and counselling services,
and condom and lubricant promotion and provision. The
estimation includes additional costs for human resources, but it
does not include costs related to HIV treatment after infection,
resistance testing, or testing and treatment of other sexually
transmitted infections. We included a 5% extra cost to allow for
the creation of an enabling environment at the project level,
programme management costs, or monitoring and evaluation costs
at the project level [32]. This 5% mark-up was chosen based on
the budget reported for management, monitoring, and evaluation
of HIV programmes at the national level [31]. We did not include
Figure 2. Selected model runs and best fit based on prevalence data for four subgroups and the overall population. Grey shading
represents selected runs; red lines represent the best fit. The runs were selected based on bounds (black bars) defined from prevalence data (blue x’s)
for four subgroups and the overall population.
doi:10.1371/journal.pmed.1001323.g002
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indirect costs such as potential earning forgone by patients or
carers. We present all costs as unadjusted market prices, specific to
Peru [31,33,34], and calculated for 10 y (i.e., the duration of our
simulated intervention).
We estimated the unit cost of a PrEP intervention to be between
US$525 and US$830, of which the main component was the cost
of PrEP drugs (over two-thirds of the total estimate). The cost of
drugs used for PrEP was set to be between US$420 and US$600
per year based on cost data provided by Gilead (for one bottle
[1 mo] supply: Viread, US$30, and Truvada, US$45, plus a 10%
to 15% distributor mark-up per bottle) [33].
For the cost-effectiveness analysis, our principal epidemiological
outcome was cost per disability-adjusted life year (DALY) averted.
PrEP implementation scenarios were assessed against a ‘‘no PrEP
intervention’’ scenario. Total number of DALYs averted was then
calculated using the number of infections averted in each scenario.
The uncertainty due to the epidemiological assumptions was
represented by adding credible intervals in our primary analysis.
These credible intervals correspond to the model runs estimating
the maximum and minimum impact of PrEP, in terms of
infections averted per person-year on PrEP. The estimated
number of DALYs associated with one HIV infection averted
was calculated as the sum of the number of years of life lost and the
number of years lost due to disability using published methods
[34,35]. These calculations included weights for Peruvian life
expectancy, age, future time, and disability. Duration of disability
was calculated on the basis of local clinical data for HIV-positive
patients presenting to care [36], and the disability weights for
HIV-related conditions were obtained from the Global Burden of
Disease study [37]. We estimated approximately 12.3 discounted
DALYs averted per infection averted, including access to ART for
80% of infected individuals. When we excluded the age weighting
function, we estimated 11.5 discounted DALYs averted. This is the
equivalent of 27.09 (and 27.12 when we exclude the age weighting
function) DALYs averted per infection averted if no discounting is
assumed, comparable to other estimates in the HIV literature
[38,39]. All details of costs and DALY estimate calculations are
given in Text S1. Future costs, savings, and health gains were
discounted at a rate of 3%. See Figures S3, S5, S6, S7, S10, and
S11 and Table S1 for a sensitivity analysis of all our results if
downstream costs of treatment averted are included in the
evaluation. The cost of ART for this analysis varied from
US$1,000 [40] to US$3,500 [38].
Currently, there is a subjective selection of cost-effectiveness
thresholds in the literature [41]. We refer to two threshold systems
commonly used. The World Health Organization Choosing
Interventions That Are Cost-Effective (WHO-CHOICE) initiative
considers an intervention to be (1) very cost-effective, if its cost is
less than the gross domestic product (GDP) per capita
(,US$5,401) per DALY averted; (2) cost-effective, if it costs
between one and three times the GDP per capita (US$5,401 to
US$16,203) per DALY averted; or (3) not cost-effective, if it costs
Table 1. Scenario definitions: impact of PrEP by adherence and functional effectiveness.
Efficacy/Adherence Adherence
iPrEx Adherence More Adherence Less Adherence
Conditional efficacy 0.92 (0.4–0.99) 0.92 (0.4–0.99) 0.92 (0.4–0.99)
Adherence 1a 0.95 0.95 0.95
Adherence 2a 0.40 0.40 0.40
Adherence 3a 0.15 0.15 0.15
Proportion in adherence group 1 0.50 0.60 0.30
Proportion in adherence group 2 0.00 0.10 0.10
Proportion in adherence group 3 0.50 0.30 0.60
Functional effectiveness 0.52 0.62 0.35
All values are proportions. Functional effectiveness is a function of the probability of transmission, the intrinsic efficacy, the adherence to PrEP, and its distribution,
affecting only unprotected sex acts, which in turn are dependent on the number of partners, average condom use, and number of sex acts per partner (all values
derived from iPrEx data [2]).
aAdherence 1, 2, and 3 refer to the proportion of doses taken consistently by an individual. The proportion in each adherence group is the population distribution (the
number of people in each adherence group). This reflects the data reported in the iPrEx study: a distribution of participants by ranges of adherence. We included a point
estimate within those ranges.
doi:10.1371/journal.pmed.1001323.t001
Table 2. Scenario definitions: impact of PrEP by coverage and
prioritisation.
Distribution Subgroup Coverage
Low Coverage
(5%)
High Coverage
(20%)
Uniform coverage Overall 0.05 0.2
MMSW 0.05 0.2
MMSM 0.05 0.2
MSW 0.05 0.2
Trans 0.05 0.2
Some prioritisation Overall 0.05 0.2
MMSW 0 0.46
MMSM 0 0.09
MSW 0.26 0.5
Trans 0.5 0.5
High prioritisation Overall 0.05 0.2
MMSW 0 0.22
MMSM 0 0.04
MSW 0.11 0.9
Trans 0.9 0.9
All values are proportions. MSW, men sex workers; trans, transwomen at higher
risk.
doi:10.1371/journal.pmed.1001323.t002
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more than three times the GDP per capita (.US$16,203) per
DALY averted. The GDP values are those estimated for Peru in
2010 [34,42]. The second threshold system we used involves more
conservative cutoff points suggested by the World Bank in 1993 for
middle-income countries [43]: ,US$100 per DALY averted to
reflect a highly cost-effective intervention, between US$100 to
US$500 for a cost-effective intervention, and .US$500 for an
intervention to be considered not cost-effective. These World Bank
cutoff points were considered in the analysis inflated to their 2010
equivalents—,US$149 for a highly cost-effective intervention and
,US$745 for a cost-effective intervention.
Analysis
We quantified the impact, cost, and cost-effectiveness of
different patterns of PrEP use across the population, identifying
dependencies on PrEP conditional efficacy, coverage, scale-up
period, prioritisation of key groups, and adherence. The impact of
risk compensation, i.e., where those on PrEP reduce condom use,
was investigated. We then used the model to find intervention
scenarios that would result in reducing the number of new
infections by one-third, representing a relevant planning target for
Lima.
Results
Key Groups to Prioritise among MSM and Transgender
People
To establish an appropriate set of strategies for using PrEP, it is
important to identify which groups to prioritise. Individuals who
might be a priority could be determined by (1) the number of
similar people and the ease of reaching them, (2) their own risk of
HIV, and (3) their relative contribution to onward transmission. In
Lima, the majority of MSM are MMSM (approximately 70%) and
MMSW (approximately 15%), but both groups experience a
relatively low risk of infection (2.5% and 1.0% modelled incidence
in 2010, respectively). Transwomen at higher risk (approximately
5%) and sex workers (approximately 10%) are smaller groups, but
are at higher risk of infection (7.3% and 3.1% modelled incidence
in 2010, respectively). A fixed amount of PrEP (25,000 person-
years) would allow covering 60% of transwomen at higher risk,
20% of sex workers, 3% of MMSM, and 16% of MMSW over
10 y. Allocated only to transwomen at higher risk or sex workers,
25,000 person-years of PrEP would be expected to avert,
respectively, 4.7% or 3.4% of infections over 10 y in the whole
population, whereas the same amount of PrEP allocated to
MMSW or MMSM would avert fewer infections: 0.9% or 1.2%,
respectively (Figure 3). For these reasons, in this epidemic context,
strategies that prioritise transwomen at higher risk and sex workers
could be expected to have higher impact for the same cost,
including amongst those not taking PrEP, because of the
prevention of downstream infection.
Potential Impact of PrEP Programmes as a Function of
Adherence, Coverage, and Prioritisation Strategies
We estimated the impact of a PrEP intervention over 10 y
under a range of implementation strategies. Figure 4 shows the
number of infections averted over 10 y (number of infections
averted per 1,000 person-years on PrEP and the proportion of
infections averted over 10 y are shown in Figures S1 and S2). For
a modest programme of 5% PrEP coverage, over 8% of infections
could be averted with an adherence level equivalent to the one
observed in the iPrEx trial and with prioritisation (high
prioritisation scenario) of the groups most likely to become
infected. Prioritising PrEP to sex workers and transwomen rather
than achieving a uniform coverage increases the impact of
interventions. This is particularly the case when overall coverage
is low. For example, for an iPrEx adherence profile, with a
coverage of 5%, the number of infections averted with a uniform
coverage strategy (970 [range 394–1,060]) more than doubles by
prioritising PrEP in a high prioritisation scenario (2,519 [range
1,086–2,713]). Increased individual adherence to PrEP increases
its estimated impact at the population level. With higher coverage
levels, the impact of PrEP interventions is greater but the relative
benefit is reduced (the numbers of infections averted per year of
PrEP decreases). This is because, in the high coverage scenario,
person-years of PrEP become relatively less efficiently allocated to
individuals with low risk.
Cost-Effectiveness of PrEP interventions
The cost per DALY averted was quantified for PrEP
interventions assuming the iPrEx profile of adherence (Figure 5,
top panel). Across all scenarios the highest estimated cost per
DALY averted (a uniform strategy at a 20% coverage level,
US$1,126–US$1,780 [uncertainty due to PrEP conditional effica-
cy: US$1,036–US$4,254) is below the WHO-CHOICE threshold
for a cost-effective intervention for Peru (,US$5,401/DALY
averted) [34], while only prioritisation scenarios (some prioritisa-
tion and high prioritisation) at low coverage, and the low bound of
a high prioritisation scenario at high coverage, are likely to be cost-
effective using the more conservative threshold suggested by the
World Bank (,US$745/DALY averted) [43]. None of the
scenarios appear to be cost-effective when the lower bound of
PrEP conditional effectiveness is included in the analysis, nor are
the scenarios considered very cost-effective using the World Bank
threshold of ,US$149/DALY averted. However, the cost per
DALY averted is substantially reduced with a high degree of
prioritisation. It could be higher in larger PrEP programmes (with
20% rather than 5% coverage). In Table 3, we present the cost-
effectiveness results for our six main scenarios, together with the
total cost over 10 y for each scenario. For the same total
investment, prioritisation improves cost-effectiveness. In Table
S1, we include the downstream ARV costs averted. PrEP
interventions could potentially be cost-effective in most scenarios,
and cost-saving in some, if the treatment costs of infections averted
are included (see Figures S5, S6, S7). Figure 5 (bottom panel)
compares the cost-effectiveness of PrEP to that estimated for other
prevention interventions in Peru [38]—the estimates for other
interventions were derived from Aldridge et al. [38], specific to
Peru. Figure 5 shows that, depending on the implementation
strategy, PrEP could be as cost-effective as treatment for sexually
transmitted infections, MSM outreach, or highly active ART. It
also suggests that PrEP should be considered as an additional
intervention available as part of a comprehensive combination
HIV prevention approach. An alternative representation of the
information in Figure 5 can be found in Figures S4, S5, S6.
Behaviour Change Associated with PrEP Use
A major issue in considering the impact of PrEP interventions is
whether individuals using PrEP will reduce how often they use
condoms. We estimated the impact of PrEP programmes making
different assumptions about condom use changes by individuals on
PrEP, ranging from complete cessation of use (2100% condom
use), to a small increase in use (+20% condom use). In Figure 6, we
show how number of infections averted and the cost per DALY
averted are affected by these changes, in the context of a low or
high coverage intervention with a high degree of prioritisation
(plots for a high prioritisation strategy including downstream ARV
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costs are given in Figure S8; results for other prioritisation
strategies including and excluding downstream ARV costs are
given in Figures S9, S10, S11, S12). Compared with no change in
behaviour, a complete cessation of condom use among those on
PrEP reduces the number of infections averted over 10 y by
between 1,500 (32%) and 2,250 (45%), and increases the cost per
DALY averted by US$200–US$315 for a high coverage
programme (blue bars). The effect is greater for a low coverage
programme (green bars). This is because only those at highest risk
of acquiring and transmitting infection are receiving PrEP, such
that each breakthrough infection has greater potential to cause
onward epidemic spread. The potential for a PrEP intervention to
have the net effect of generating more new infections is
theoretically possible but highly unlikely, requiring that the lowest
empirical estimate of intrinsic efficacy of PrEP be true (40% is the
lower bound of the confidence interval of effectiveness among
participants with drug levels in their blood [95% CI 40–99]) and
that all users reduce their condom use by at least 50% (results not
shown). We further explored two different scenarios where
behaviour change was correlated with adherence and found that
the effect on HIV incidence of behavioural change in those with
high adherence is only modest (because if individuals do
consistently take the PreP pills, then the degree of protection is
very high). The effect of behaviour change on incidence is greater
if those with bad adherence are found to change their behaviour
(Figure S12). Nevertheless, communication programmes to limit
risk compensation may be a cost-effective complement to PrEP
interventions.
Averting One-Third of New Infections Using PrEP
Finally, we identify alternative strategies that would be expected
to reduce the number of infections over 10 y by one-third
(Table 4). With a rapid scale-up of 2 y and a highly prioritised
strategy, a minimum of 435,000 PrEP person-years would be
required, at an estimated cost of US$196 million to US$310
million over 10 y. The same impact would be generated with a
slower scale-up and a uniform distribution, but at a higher cost:
US$277million to US$439 million over 10 y. With all strategies,
modelling a longer period to reach an intended coverage level
increases the amount of person-years on PrEP needed. The total
cost and cost-effectiveness of different PrEP strategies to avert one-
third of infections, including downstream ARV costs averted, are
shown in Table S1. While the resources needed are still important
in these scenarios, the cost-effectiveness is greatly improved.
Discussion
We estimated the potential impact of PrEP under different
intervention scenarios, examining the relative importance of
implementation strategies and individual adherence. Our model
shows an important epidemiological impact of PrEP use, largely
driven by the characteristics of the implementation programme—
PrEP conditional efficacy, coverage, prioritisation strategy, and
time to scale up—and risk compensation behaviour.
Overall, if downstream ARV costs averted are not included,
PrEP is predicted to be cost-effective in this population by the
WHO-CHOICE guidelines, and borderline cost-effective by the
more conservative World Bank guidelines, if the intervention is
prioritised to those most vulnerable to infection. If downstream
ARV costs are included, most PrEP scenarios are found to be cost-
effective. This argues for PrEP to be considered among the set of
efficacious and cost-effective interventions that could be included
in a comprehensive combination of HIV prevention interventions
for MSM in this setting. Consistent with the significant heteroge-
neity in risk behaviours among MSM and transwomen at higher
risk, our results show that prioritising people in higher risk groups
Figure 3. Proportion of total new infections averted over 10 y by giving 25,000 PrEP person-years to each subgroup in isolation.
The error bars reflect the iPrEx efficacy estimate of 92% (95% CI 40–99).
doi:10.1371/journal.pmed.1001323.g003
Cost-Effectiveness of PrEP in MSM Populations
PLOS Medicine | www.plosmedicine.org 7 October 2012 | Volume 9 | Issue 10 | e1001323
(e.g., transwomen at higher risk) when implementing PrEP would
have the largest impact. While risk compensation could reduce the
impact of PrEP, our results suggest that, under a range of
assumptions, PrEP is still likely to be cost-effective.
A higher coverage strengthens the impact on incidence over
10 y, as does a rapid scale-up of the intervention. However,
implementation of PrEP in isolation to a scale that it would arrest
the epidemic would require more resources than have been
available. To reduce new infections by one-third, the total cost of
introducing PrEP will amount to at least US$20 million on average
per year (over US$200 million over 10 years). As a comparison,
total HIV spending (prevention, treatment, and care) in Peru for
the year 2009 was reported to be just over US$40 million [44].
Furthermore, while Peru has been an important aid recipient from
The Global Fund to Fight AIDS, Tuberculosis and Malaria in
Latin America, the total approved HIV grant amount to date has
been just over US$85 million [45].
The modelling results presented here are one of the first to
quantify the potential population impact of PrEP incorporating
data from the only clinical trial carried out in an MSM population.
We highlighted the need to represent heterogeneity in adherence
behaviour together with a high intrinsic efficacy of PrEP (when
adherence is high). It is also to our knowledge the first model to
examine the impact among MSM and transwomen in a low- or
middle-income country.
Our results are broadly consistent with previous modelling work
on the impact of PrEP among MSM in the US, where most
authors have found that while PrEP might be cost-effective under
certain assumptions, the investment needed remains very high. For
instance, Desai et al. [46] found that a PrEP program was cost-
effective under most variations in efficacy and adherence—a high
impact was possible for an efficacy of 70% and program adherence
of 50%. Paltiel et al. [47] also found that PrEP could have a
substantial effect on lifetime HIV infection risk, especially among
younger populations, and that it could be a cost-saving interven-
tion with drug efficacy levels over 70% and an annual PrEP cost of
US$2,500 or less. Recently, Koppenhaver et al. [48] found that
although reductions in new HIV cases following PrEP introduc-
tion among MSM in New York City led to substantial reductions
in treatment costs, these savings were largely offset by increases in
PrEP costs. The authors assumed both high costs for PrEP—
including costs for implementing PrEP and for tenofovir/
emtricitabine (valued at $22/d)—and a coverage of 100% of all
susceptible. Juusola et al. [49] varied the coverage of susceptible
Figure 4. Estimated impact of PrEP with respect to coverage, adherence, and prioritisation of key populations. The error bars reflect
the uncertainty in the iPrEx efficacy estimate of 92% (95% CI 40–99). In this comparison, we show two scenarios (low coverage in green [A]; high
coverage in blue [B]) including three prioritisation strategies—uniform, where the coverage is the same in each subgroup; some prioritisation, where
higher coverage is achieved in the transwomen at higher risk and sex worker populations (but no more than 50% covered) than in MMSM and
MMSW; and high prioritisation, where 90% of transwomen at higher risk and 11% of sex workers receive PrEP in the low coverage scenario, or 90% of
transwomen at higher risk, 90% of sex workers, 3.9% of MMSM, and 21.5% of MMSW receive PrEP in the high coverage scenario.
doi:10.1371/journal.pmed.1001323.g004
Cost-Effectiveness of PrEP in MSM Populations
PLOS Medicine | www.plosmedicine.org 8 October 2012 | Volume 9 | Issue 10 | e1001323
MSM and also included high costs of PrEP consistent with US
costs. Juusola et al. [49] concluded that ‘‘PrEP in the general
MSM population could prevent a substantial number of HIV
infections, but it is expensive’’.
Results from modelling studies of PrEP use in generalised
epidemics have been conflicting. Abbas et al. [50] found that with
high effectiveness, PrEP could have a beneficial impact when
targeted to those at highest risk, if it did not lead to an increase in
risk behaviours. Recently, Pretorius et al. [39] found a PrEP
intervention to be cost-effective according to the WHO-CHOICE
threshold, but concluded that it did not provide value for money
when compared to the scale-up of ART. Hallett et al. [51] found
the use of PrEP in serodiscordant couples to be a cost-effective
alternative, especially in couples with increased risk behaviours.
Although our findings cannot be directly compared with these, as
the settings differ greatly, one explanation for the different results
obtained could be the difference in incidence assumptions (higher
incidence rates among MSM lead to prevention interventions
having a greater value).
Our study balances heterogeneity considerations with data
availability and the programmatic relevance of distinguishing
particular subgroups, but it has limitations. The model is limited
by the need to capture important variation and complexity in
sexual behaviour in this population into a simplified framework.
To account for this, we applied a Bayesian model calibration
procedure. Because of the large amount of consistent prevalence
data available for MSM and transwomen in Lima, the best fit was
used in our analysis. However, we explored the potential effect of
uncertainty around the best fit epidemiological scenario on our
main outputs (i.e., the cost-effectiveness of PrEP across all
programmatic scenarios) and observed that although the range is
broad, it does not change the main conclusions from this analysis.
The model does not capture the possibility of evolution of drug
resistance generated by individuals using PrEP after breakthrough
Figure 5. Cost-effectiveness of PrEP, estimated as cost per DALY averted. The top panel shows PrEP cost per DALY averted with regard to
coverage levels and strategies. The bottom panel shows a comparison of PrEP cost per DALY averted with other HIV prevention strategies. The error
bars reflect the uncertainty in the iPrEx efficacy estimate of 92% (95% CI 40–99). The height of the bars shows the variation due only to the cost
assumptions of one person-year on PrEP. In the top panel, the iPrEx adherence profile is used for the scenarios. In green: low coverage scenario: 5%;
in blue: high coverage scenario: 20%. In the bottom panel, the variation in cost for the interventions reflects different coverage strategies assumed
and the uncertainty in the costing. Values from Aldridge et al. [38] presented in this paper were calculated using assumptions from the GOALS model
on coverage and intervention design (see also Stover et al. [54]). PrEP estimated cost/DALY was calculated for both uniform and high prioritisation
strategies (including 5% and 20% coverage scenarios). The red lines correspond to (1) the World Bank threshold for a cost-effective intervention,
,US$745/DALY averted, and (2) the World Bank threshold for a highly cost-effective intervention, ,US$149/DALY averted. FSW, female sex worker;
HAART, highly active ART; STI, sexually transmitted infection; VCT, voluntary counselling and testing.
doi:10.1371/journal.pmed.1001323.g005
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Table 3. Cost-effectiveness and total cost of PrEP over 10 y.
Distribution Coveragea (Proportion)
Total
Person-
Yearsb
Cost/DALY: Cost
Assumptions Onlyc (US
Dollars)
Cost/DALY: Total
Uncertaintyd (US
Dollars) Total Coste (US Dollars)
Uniform 0.05 45,325 1,076–1,702 419–4,182 23,795,696–37,619,863
Uniform 0.20 182,596 1,125–1,779 428–4,254 95,863,381–151,555,440
Some prioritisation 0.05 (0, 0, 0.26, 0.5) 44,925 447–707 159–1,596 23,852,467–37,709,615
Some prioritisation 0.20 (0.04, 0.08, 0.5, 0.5) 187,116 886–1,400 397–3,133 96,398,735–152,401,810
High prioritisation 0.05 (0, 0, 0.11, 0.9) 44,002 403–637 163–1,553 23,877,220–37,748,747
High prioritisation 0.20 (0.21, 0.03, 0.9, 0.9) 183,851 665–1,052 310–2,258 96,071,585–151,884,601
Downstream ARV costs averted not included.
aCoverage in the uniform distribution strategy is equal in all subgroups (MMSW, MMSM, sex workers, and transwomen at higher risk). The coverage showed in both
strategies involving prioritisation (some and high) are given as overall population coverage and, in parentheses, the coverage in each subpopulation (MMSW, MMSM,
sex workers, transwomen at higher risk).
bTotal number of person-years on PrEP over 10 ys.
cVariation in the cost/DALY due to cost assumptions only (corresponding to the height of the coloured bars in the top panel of Figure 5).
dVariation due to total uncertainty, including both cost and PrEP efficacy assumptions as well as epidemiological assumptions.
eTotal cost of PrEP intervention over 10 y; the range reflects the uncertainty of PrEP programme costs only.
doi:10.1371/journal.pmed.1001323.t003
Figure 6. Population impact and cost of PrEP with respect to changes in condom use for a high prioritisation strategy. The top panel
shows behaviour change and population impact of PrEP. The bottom panel shows behaviour change and PrEP cost per infection averted. This figure
assumes there is no correlation between adherence and risk compensation. We explore this issue separately in Figure S12. The iPrEx adherence
profile was used for these scenarios. In green: low coverage scenario: 5%; in blue: high coverage scenario: 20%. The red lines correspond to (1) the
World Bank threshold for a cost-effective intervention, ,US$745/DALY averted, and (2) the World Bank threshold for a highly cost-effective
intervention, ,US$149/DALY averted. The height of the bars shows the variation due only to the cost assumptions of one person-year on PrEP.
doi:10.1371/journal.pmed.1001323.g006
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infection, which has been a concern. However, several models
suggest that the amount of resistance generated by individuals
using PrEP after breakthrough infection will be small compared
to that generated by ART itself [52], provided individuals on
PrEP are tested frequently. Our results suggest that only four of
every 1,000 PrEP person-years would be wrongly allocated to
infected individuals (in a low coverage, high prioritisation
scenario) if individuals on PrEP are tested every 3 mo. This
increases to eight of every 1,000 PrEP person-years if the delay
between tests is set to every 6 mo (results not shown). Moreover,
Supervie et al. [53] recently used a mathematical model to
explore resistance in the context of PrEP use in the MSM
community of San Francisco, California, showing that if risk
behaviours did not increase, then transmitted resistance would
decline with PrEP.
Furthermore, the validity of DALYs as an aggregate measure
of effectiveness depends on assumptions made for disability
weighting, discounting, age weighting, and life expectancy. We
followed standard practices regarding these assumptions, aiming
to increase the comparability of our analysis while providing
meaningful results for policy-makers. However, we recognise that
standard assumptions about DALYs averted by averting HIV
transmission do not fully consider strong preferences to remain
HIV-uninfected, given the burden of lifelong daily therapy and
stigma associated with HIV infection. In addition, we limited the
calculation of the total DALYs averted to a function of the
number of infections averted during the 10-y intervention period,
assuming 80% of these would have received treatment otherwise.
By doing this, we provide a conservative estimate of the cost-
effectiveness of PrEP (i.e., not including the savings due to
treatment costs averted). However, this could also represent an
optimistic approximation of potential benefits, as we assume that
those infections averted during the intervention will not happen
afterwards. We tested this by running the model for an additional
60 y after the end of the intervention and found that the number
of infections averted overall is greater than that observed during
the intervention period (results available in Text S1). The spread
of infection is a dynamic process; stopping infections during one
period protects others from being infected further down the line
in a similar way that vaccines do. We did not use this information
to produce results, to ensure comparability with other cost-
effectiveness analyses using mathematical models of HIV
transmission. Additionally, recognising that we made a large
number of assumptions to estimate the effect of PrEP during the
10 y of the intervention, we preferred not to extrapolate beha-
vioural assumptions afterwards.
Another limitation of this study is that interactions between
PrEP and earlier treatment for prevention of onward transmission
are not fully considered. How PrEP and treatment programs will
interact in practice remains to be learned. Although capacity for
manufacturing ARV drugs, including generic formulations of the
most popular agents, has not been limiting, the funding available
to purchase these drugs has. Theoretically, PrEP could compete
with treatment scale-up by using limited funding or limited clinic
capacity, and this should be avoided. Alternatively, PrEP could
enable treatment programs, by allowing greater volume discounts
on drug prices and costs, by increasing testing coverage, by
fostering retention in treatment by destigmatizing ARV drugs and
the people who use them, or by fostering popular and political
support for attracting more funding to HIV/AIDS initiatives. In
the absence of information about how these various possibilities
will play out, this paper has aimed to evaluate the potential impact
of PrEP as a prevention strategy among a population with
relatively high risk of infection and to explore the effect of different
programmatic factors such as prioritisation and coverage. While
widespread treatment is assumed in this model in the context of
universal ART access along current guidelines, a detailed analysis
of how PrEP could affect treatment coverage is beyond the scope
of available information at this time.
In conclusion, we have shown that if it is prioritised to key
groups and has a rapid scale-up, PrEP could be a cost-effective
intervention for MSM populations and transwomen in Lima,
Peru. Despite cost-effectiveness at apparently feasible levels of
coverage and uptake, considerable expenditures and human
resources will be required to generate a significant reduction in
incidence. These expenditures should not be considered unless
well-performing ART services are already in place, which is not
the case everywhere in Peru, and even less so across the region. If
such conditions are assured, however, a strategically implemented
PrEP programme could make a significant contribution as part of
a combination package of priority, well-implemented interventions
for MSM/transwomen populations in concentrated epidemics
after a scale-up of ART.
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Table 4. Scenarios to achieve one third of new infections averted over 10 y.
Distribution Scale-Up Coveragea (Proportion)
Total Person-
Yearsb
Cost/DALYc (US
Dollars) Total Costd (US Dollars)
Uniform Two years 0.46 597,165 1,189–1,880 269,888,000–426,680,500
Uniform Five years 0.57 625,155 1,263–1,996 277,445,500–438,628,500
Some prioritisation Two years 0.40 (0.26/0.38/0.63/0.63) 521,040 1,046–1,654 235,447,000–372,232,000
Some prioritisation Five years 0.54 (0.51/0.51/0.7/0.7) 591,730 997–1,879 262,597,000–415,153,500
High prioritisation Two years 0.34 (0.27/0.22/0.9/0.9) 433,810 870–1,375 195,959,000–309,802,000
High prioritisation Five years 0.49 (0.42/0.41/0.9/0.9) 535,155 1,073–1,696 237,555,000–375,563,000
aCoverage in the uniform distribution strategy is equal in all subgroups (MMSW, MMSM, sex workers, and transwomen at higher risk). The coverage showed in both
strategies involving prioritisation (some and high) are given as overall population coverage and, in parentheses, the coverage in each subpopulation (MMSW/MMSM/
sex workers/transwomen at higher risk).
bTotal number of person-years on PrEP over 10 y.
cThe range represents the variation observed in the estimated costs per PrEP person-year.
dTotal cost of PrEP intervention over 10 y; the range represents the variation observed in the estimated costs per PrEP person-year.
doi:10.1371/journal.pmed.1001323.t004
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Figure S1 Estimated impact of PrEP with respect to
coverage, adherence, and prioritisation of key popula-
tions: number of infections averted/1,000 PrEP person-
years. Impact is shown as infections averted for every 1,000 PrEP
person-years (PY). The error bars reflect the uncertainty in the
iPrEx efficacy estimate of 92% (95% CI 40–99). In this
comparison, we show two scenarios ([A]: low coverage, in green;
[B]: high coverage, in blue) for three adherence profiles including
three prioritisation strategies—uniform, where the coverage is the
same in each subgroup; some prioritisation, where there is higher
coverage achieved in the transwomen at higher risk and sex
worker populations (but no more than 50% covered) than in
MMSW and MMSM; and high prioritisation, where 90% of
transwomen at higher risk and 11% of sex workers receive PrEP in
the low coverage scenario, or 90% of transwomen at higher risk,
90% of sex workers, 3.9% of MMSM, and 21.5% of MMSW
receive PrEP in the high coverage scenario.
(TIFF)
Figure S2 Estimated impact of PrEP with respect to
coverage, adherence, and prioritisation of key popula-
tions: proportion of infections averted over 10 y. Impact is
shown as percentage of total infections that are averted with PrEP.
The error bars reflect the uncertainty in the iPrEx efficacy estimate
of 92% (95% CI 40–99). In this comparison, we show two
scenarios ([A]: low coverage, in green; [B]: high coverage, in blue)
for three adherence profiles including three prioritisation strate-
gies—uniform, where the coverage is the same in each subgroup;
some prioritisation, where there is higher coverage achieved in the
transwomen at higher risk and sex worker populations (but no
more than 50% covered) than in MMSW and MMSM; and high
prioritisation, where 90% of transwomen at higher risk and 11%
of sex workers receive PrEP in the low coverage scenario, or 90%
of transwomen at higher risk, 90% of sex workers, 3.9% of
MMSM, and 21.5% of MMSW receive PrEP in the high coverage
scenario.
(TIFF)
Figure S3 Cost-effectiveness of PrEP, estimated as cost
per DALY averted: downstream ARV costs included. (A)
Downstream ARV costs averted included at US$1,000/person-
year on ARV drugs. (B) Downstream ARV costs averted included
at US$3,500/person-year on ARV drugs. iPrEx adherence profile
used for these scenarios. In green: low coverage scenario: 5%; in
blue: high coverage scenario: 20%. The variation in costs reflects
the uncertainty in the costing of one person-year on PrEP. The red
lines correspond to (1) the World Bank threshold for a cost-
effective intervention, ,US$745/DALY averted, and (2) the
World Bank threshold for a highly cost-effective intervention,
,US$149/DALY averted.
(TIFF)
Figure S4 Cost-effectiveness and total cost of PrEP over
10 y: downstream ARV costs not included. iPrEx adher-
ence profile used for all scenarios. In green: low coverage scenario:
5%; in blue: high coverage scenario: 20%. Lines are plotted
against the y-axis of cost/DALY averted in US dollars and against
the x-axis—total number of DALYs averted over 10 y. The
numbers over the lines indicate the data points as follows: 1, low
coverage, uniform scenario; 2, low coverage, some prioritisation
scenario; 3, low coverage, high prioritisation scenario; 4, high
coverage, uniform scenario; 5, high coverage, some prioritisation
scenario; 6, high coverage, high prioritisation scenario. These data
points have uncertainty bars representing the variation in the
costing of one person-year on PrEP. The boxes are plotted against
the right-hand axis only. They represent the total cost of scenarios.
The variation in costs (height of boxes) reflects the uncertainty in
the costing of one person-year on PrEP.
(TIFF)
Figure S5 Cost-effectiveness and total cost of PrEP over
10 y: downstream ARV costs averted included at
US$1,000/person-year on ARV drugs. iPrEx adherence
profile used for all scenarios. In green: low coverage scenario:
5%; in blue: high coverage scenario: 20%. Lines are plotted
against the y-axis of cost/DALY averted in US dollars and against
the x-axis—total number of DALYs averted over 10 y. The
numbers over the lines indicate the data points as follows: 1, low
coverage, uniform scenario; 2, low coverage, some prioritisation
scenario; 3, low coverage, high prioritisation scenario; 4, high
coverage, uniform scenario; 5, high coverage, some prioritisation
scenario; 6, high coverage, high prioritisation scenario. These data
points have uncertainty bars representing the variation in the
costing of one person-year on PrEP. The boxes are plotted against
the righthand axis only. They represent the total cost of scenarios.
The variation in costs (height of boxes) reflects the uncertainty in
the costing of one person-year on PrEP.
(TIFF)
Figure S6 Cost-effectiveness and total cost of PrEP over
10 y: downstream ARV costs averted included at
US$3,500/person-year on ARV drugs. iPrEx adherence
profile used for all scenarios. In green: low coverage scenario:
5%; in blue: high coverage scenario: 20%. Lines are plotted
against the y-axis of cost/DALY averted in US dollars and against
the x-axis—total number of DALYs averted over 10 y. The
numbers over the lines indicate the data points as follows: 1, low
coverage, uniform scenario; 2, low coverage, some prioritisation
scenario; 3, low coverage, high prioritisation scenario; 4, high
coverage, uniform scenario; 5, high coverage, some prioritisation
scenario; 6, high coverage, high prioritisation scenario. These data
points have uncertainty bars representing the variation in the
costing of one person-year on PrEP. The boxes are plotted against
the righthand axis only. They represent the total cost of scenarios.
The variation in costs (height of boxes) reflects the uncertainty in
the costing of one person-year on PrEP.
(TIFF)
Figure S7 Cost of PrEP with respect to changes in
condom use for a high prioritisation strategy. (A)
Downstream ARV costs averted included at US$1,000/person-
year on ARV drugs. (B) Downstream ARV costs averted included
at US$3,500/person-year on ARV drugs. This figure assumes
there is no correlation between adherence and risk compensation.
We explore this issue separately in Figure S12. iPrEx adherence
profile used for these scenarios. In green: low coverage scenario:
5%; in blue: high coverage scenario: 20%. The red lines
correspond to (1) the World Bank threshold for a cost-effective
intervention, ,US$745/DALY averted, and (2) the World Bank
threshold for a highly cost-effective intervention, ,US$149/
DALY averted.
(TIFF)
Figure S8 Population impact of PrEP with respect to
changes in condom use. (A) ‘‘Uniform’’ scenario. (B) ‘‘Some
prioritisation’’ scenario. This figure assumes there is no correlation
between adherence and risk compensation. We explore this issue
separately in Figure S12. In green: low coverage scenario: 5%; in
blue: high coverage scenario: 20%. Reference is no change in
condom use.
(TIFF)
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Figure S9 Cost-effectiveness of PrEP with respect to
changes in condom use: downstream ARV costs averted
not included. (A) ‘‘Uniform’’ scenario. (B) ‘‘Some prioritisation’’
scenario. This figure assumes there is no correlation between
adherence and risk compensation. We explore this issue separately
in Figure S12. iPrEx adherence profile used for these scenarios. In
green: low coverage scenario: 5%; in blue: high coverage scenario:
20%. The red lines correspond to (1) the World Bank threshold for
a cost-effective intervention, ,US$745/DALY averted, and (2)
the World Bank threshold for a highly cost-effective intervention,
,US$149/DALY averted.
(TIFF)
Figure S10 Cost-effectiveness of PrEP with respect to
changes in condom use: downstream ARV costs averted
included at US$1,000/person-years on ARV drugs. (A)
‘‘Uniform’’ scenario. (B) ‘‘Some prioritisation’’ scenario. This
figure assumes there is no correlation between adherence and risk
compensation. We explore this issue separately in Figure S12.
iPrEx adherence profile used for these scenarios. In green: low
coverage scenario: 5%; in blue: high coverage scenario: 20%. The
red lines correspond to (1) the World Bank threshold for a cost-
effective intervention, ,US$745/DALY averted, and (2) the
World Bank threshold for a highly cost-effective intervention,
,US$149/DALY averted.
(TIFF)
Figure S11 Cost-effectiveness of PrEP with respect to
changes in condom use: downstream ARV costs averted
included at US$3,500/person-year on ARV drugs. (A)
‘‘Uniform’’ scenario. (B) ‘‘Some prioritisation’’ scenario. This
figure assumes there is no correlation between adherence and risk
compensation. We explore this issue separately in Figure S12.
iPrEx adherence profile used for these scenarios. In green: low
coverage scenario: 5%; in blue: high coverage scenario: 20%. The
red lines correspond to (1) the World Bank threshold for a cost-
effective intervention, ,US$745/DALY averted, and (2) the
World Bank threshold for a highly cost-effective intervention,
,US$149/DALY averted.
(TIFF)
Figure S12 Population impact of PrEP with respect to
differential changes in condom use. (A) Only good adherers
change their behaviour. (B) Only bad adherers change their
behaviour. This figure assumes there is a correlation between
adherence and risk compensation. iPrEx adherence profile used
for these scenarios. In green: low coverage scenario: 5%; in blue:
high coverage scenario: 20%. Reference is no change in condom
use.
(TIFF)
Table S1 Scenarios to achieve one-third of new infec-
tions averted over 10 y: downstream ARV costs averted
included at US$1,000 and 3,500/person-year on ARV
drugs. Total PY: total number of person-years on PrEP over
10 y. Cost/DALY: cost in US dollars/DALY. Total cost: total cost
of PrEP intervention over 10 y. (1) Includes downstream ARV
costs averted included at US$1,000/person-year on ARV drugs.
(2) Includes downstream ARV costs averted included at
US$3,500/person-year on ARV drugs. The range observed in
this column and in the Total cost column represents the variation
observed in the costs per PrEP person-year. Coverage in the
uniform distribution strategy is equal in all subgroups (MMSW,
MMSM, sex workers, and transwomen at higher risk). The
coverage showed in both strategies involving prioritisation (some
and high) are given as overall population coverage and, in
brackets, the coverage in each subpopulation (MMSW/MMSM/
sex workers/transwomen at higher risk).
(DOC)
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Editors’ Summary
Background Without a vaccine, the only ways to halt the
global HIV epidemic are prevention strategies that reduce
transmission of the HIV virus. Up until recently, behavioral
strategies such as condom use and reduction of sexual
partners have been at the center of HIV prevention. In the
past few years, several biological prevention measures have
also been shown to be effective in reducing (though not
completely preventing) HIV transmission. These include male
circumcision, treatment for prevention (giving antiretroviral
drugs to HIV-infected people, before they need it for their
own health, to reduce their infectiousness) and pre-exposure
prophylaxis (or PrEP), in which HIV-negative people use
antiretroviral drugs to protect themselves from infection.
One PrEP regimen (a daily pill containing two different
antiretrovirals) has been shown in a clinical trial to reduce
new infections by 44% in of men who have sex with men
(MSM). In July 2012, the US Food and Drug Administration
approved this PrEP regimen to reduce the risk of HIV
infection in uninfected men and women who are at high risk
of HIV infection and who may engage in sexual activity with
HIV-infected partners. The approval makes it clear that PrEP
needs to be used in combination with safe sex practices.
WhyWas This Study Done? Clinical trials have shown that
PrEP can reduce HIV infections among participants, but they
have not examined the consequences PrEP could have at the
population level. Before decision-makers can decide whether
to invest in PrEP programs, they need to know about the
costs and benefits at the population level. Besides the price
of the drug itself, the costs include HIV testing before
starting PrEP, as well as regular tests thereafter. The health
benefits of reducing new HIV infections are calculated in
‘‘disability-adjusted life years’’ (or DALYs) averted. One DALY
is equal to one year of healthy life lost. Other benefits include
future savings in lifelong HIV/AIDS treatment for every
person whose infection is prevented by PrEP.
This study estimates the potential costs and health benefits
of several hypothetical PrEP roll-out scenarios among the
community of MSM in Lima, Peru. The scientists chose this
community because many of the participants in the clinical
trial that showed that PrEP can reduce infections came from
this community, and they therefore have some knowledge
on how PrEP affects HIV infection rates and behavior in this
population. Because the HIV epidemic in Lima is concentrat-
ed among MSM, similar to most of Latin America and several
other developed countries, the results might also be relevant
for the evaluation of PrEP in other places.
What Did the Researchers Do and Find? For their
scenarios, the researchers looked at ‘‘high coverage’’ and
‘‘low coverage’’ scenarios, in which 20% and 5% of
uninfected individuals use PrEP, respectively. They also
divided the MSM community into those at lower risk of
becoming infected and those at higher risk. The latter group
consisted of transwomen at higher risk (transsexuals and
transvestites with many sexual partners) and male sex
workers. In a ‘‘uniform coverage’’ scenario, PrEP is equally
distributed among all MSM. ‘‘Prioritized scenarios’’ cover
transwomen at higher risk and sex workers preferentially.
Two additional important factors for the estimated benefits
are treatment adherence (i.e., whether people take the pills
they have been prescribed faithfully over long periods of
time even though they are not sick) and changes in risk
behavior (i.e., whether the perceived protection provided by
PrEP leads to more unprotected sex).
The cost estimates for PrEP included the costs of the drug
itself and HIV tests prior to PrEP prescription and at three-
month intervals thereafter, as well as outreach and counsel-
ing services and condom and lubricant promotion and
provision.
To judge whether under the various scenarios PrEP is cost-
effective, the researchers applied two commonly used but
different cost-effectiveness thresholds. The World Health
Organization’s WHO-CHOICE initiative considers an interven-
tion cost-effective if its cost is less than three times the gross
domestic product (GDP) per capita per DALY averted. For
Peru, this means an intervention should cost less than
US$16,302 per DALY. The World Bank has more stringent
criteria: it considers an intervention cost-effective for a
middle-income country like Peru if it costs less than US$500
per DALY averted.
The researchers estimate that PrEP is cost-effective in Lima’s
MSM population for most scenarios by WHO-CHOICE
guidelines. Only scenarios that prioritize PrEP to those most
likely to become infected (i.e., transwomen at higher risk and
sex workers) are cost-effective (and only barely) by the more
stringent World Bank criteria. If the savings on antiretroviral
drugs to treat people with HIV (those who would have
become infected without PrEP) are included in the calcula-
tion, most scenarios become cost-effective, even under
World Bank criteria.
The most cost-effective scenario, namely, having a modest
coverage of 5%, prioritizing PrEP to transwomen at higher
risk and sex workers, and assuming fairly high adherence
levels among PrEP recipients, is estimated to avert about 8%
of new infections among this community over ten years.
What Do these Findings Mean? These findings suggest
that under some circumstances, PrEP could be a cost-
effective tool to reduce new HIV infections. However, as the
researchers discuss, PrEP is expensive and only partly
effective. Moreover, its effectiveness depends on two
behavioral factors—adherence to a strict drug regimen and
continued practicing of safe sex—both of which remain hard
to predict. As a consequence, PrEP alone is not a valid
strategy to prevent new HIV infections. It needs instead to be
considered as one of several available tools. If and when PrEP
is chosen as part of an integrated prevention strategy will
depend on the specific target population, the overall funds
available, and how well its cost-effectiveness compares with
other prevention measures.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001323.
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N NAM/aidsmap provides basic information about HIV/AIDS,
summaries of recent research findings on HIV care and
treatment, and a section on PrEP
N Information is available from Avert, an international AIDS
charity, on many aspects of HIV/AIDS, including HIV
prevention
N AVAC Global Advocacy for HIV Prevention provides up-to-
date information on HIV prevention, including PrEP
N The US Centers for Disease Control and Prevention also has
information on PrEP
N The World Health Organization has a page on its WHO-
CHOICE criteria for cost-effectiveness
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